Exploring the Immunoprotective Potential of a Nanocarrier Immersion Vaccine Encoding Sip against Streptococcus Infection in Tilapia ( Oreochromis niloticus )

Tilapia, as one of the fish widely cultured around the world, is suffering severe impact from the disease with the deterioration of the breeding environment and the increasing of breeding density, which brings serious economic loss to tilapia farming. In this study, the surface immunogenic protein (...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 11; no. 7; p. 1262
Main Authors Cao, Ye, Liu, Jia, Liu, Gaoyang, Du, Hui, Liu, Tianqiang, Wang, Gaoxue, Wang, Qing, Zhou, Ya, Wang, Erlong
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 20.07.2023
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Tilapia, as one of the fish widely cultured around the world, is suffering severe impact from the disease with the deterioration of the breeding environment and the increasing of breeding density, which brings serious economic loss to tilapia farming. In this study, the surface immunogenic protein (Sip) of ( ) was selected as the potential candidate antigen and connected with bacterial nano cellulose (BNC) to construct the nanocarrier subunit vaccine (BNC-rSip), and the immersion immune effects against and ( ) in Nile tilapia were evaluated on the basis of the serum antibody level, non-specific enzyme activity, the immune-related gene expression and relative percent survival (RPS). The results indicated that Sip possessed the expected immunogenicity according to the immunoinformatic analysis. Compared with the rSip group, BNC-rSip significantly induced serum antibody production and improved the innate immunity level of tilapia. After challenge, the RPS of BNC-rSip groups were 78.95% ( ) and 67.86% ( ), which were both higher than those of rSip groups,31.58% ( ) and 35.71% ( ), respectively. Our study indicated that BNC-rSip can induce protective immunity for tilapia through immersion immunization and may be an ideal candidate vaccine for controlling tilapia streptococcal disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines11071262